BMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyJust a few days after Biogen abandoned its tau-targeting Alzheimer’s disease candidate gosuranemab, Bristol-Myers Squibb has opted into Share XBMS re-joins Alzheimer’s push, paying $80m for Prothena’s tau antibodyhttps://pharmaphorum.com/news/bms-re-joins-alzheimers-push-paying-80m-for-prothenas-tau-antibody/
Biogen abandons tau antibody for Alzheimer’s after phase 2 missBiogen has four other Alzheimer’s candidates in its clinical pipeline behind recently-approved Aduhelm, but one of them – Share XBiogen abandons tau antibody for Alzheimer’s after phase 2 misshttps://pharmaphorum.com/news/biogen-abandons-tau-antibody-for-alzheimers-after-phase-2-miss/
Early data back J&J and AC Immune’s Alzheimer’s jabShares in Swiss biotech AC Immune have risen sharply after it said a vaccine in development for Alzheimer’s Share XEarly data back J&J and AC Immune’s Alzheimer’s jabhttps://pharmaphorum.com/news/early-data-back-jj-and-ac-immunes-alzheimers-jab/
AC Immune poleaxed on Alzheimer’s study failShares in AC Immune have collapsed after partner Genentech revealed its tau-targeting Alzheimer’s drug semorinemab had flunked a Share XAC Immune poleaxed on Alzheimer’s study failhttps://pharmaphorum.com/news/ac-immune-poleaxed-on-alzheimers-study-fail/
Roche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mRoche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a Share XRoche doubles down on tau for Alzheimer’s, licensing UCB drug for $120mhttps://pharmaphorum.com/news/roche-doubles-down-on-tau-for-alzheimers-licensing-ucb-drug-for-120m/
A bright future for CNS and Alzheimer’s?Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare Share XA bright future for CNS and Alzheimer’s?https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/
